Puretech Health

PureTech Health's KarXT, now marketed as Cobenfy, receives FDA approval for treating schizophrenia in adults, triggering $29m in payments from Royalty Pharma and Karuna Therapeutics. Cobenfy, developed by combining xanomeline with trospium chloride, aims to address tolerability issues in neuropsychiatric treatments. PureTech anticipates 2% royalties on net annual sales exceeding $2bn, with Cobenfy's success generating $1.1bn for the company, enabling self-funding of its pipeline, including LYT-100 for idiopathic pulmonary fibrosis.

FDA approves Bristol Myers Squibb's Cobenfy, the first new class of schizophrenia treatment in over 3 decades, targeting M1 and M4 receptors without blocking D2 receptors.

PureTech-invented KarXT receives FDA approval for schizophrenia treatment, triggering $29M in milestone payments and potential future royalties. KarXT, now marketed as Cobenfy by Bristol Myers Squibb, is the first new drug mechanism for schizophrenia in over 50 years.

PureTech Health announced FDA approval of KarXT for schizophrenia, triggering $29 million in milestone payments from Royalty Pharma and Karuna Therapeutics, acquired by Bristol Myers Squibb in 2024. KarXT will be marketed as Cobenfy, the first new drug mechanism for schizophrenia in over 50 years.

Insilico Medicine's AI-designed drug ISM001-055 shows positive Phase 2a results for idiopathic pulmonary fibrosis (IPF), with dose-dependent improvement in forced vital capacity (FVC). The drug targets TNIK enzyme, identified via generative AI, and is set for further Phase 2b studies. Competitors include Boehringer Ingelheim's nerandomilast and Pliant Therapeutics' bexotegrast, both showing promising results in IPF treatment.

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

Alliance News supplies Morningstar with ongoing coverage of news impacting listed companies.

Vor Bio's Phase 1/2 VBP101 study shows trem-cel + Mylotarg reliable engraftment, shielding, broadened therapeutic window, and patient benefit in relapsed/refractory AML. VCAR33ALLO and new asset VADC45 show potential in oncology, gene therapy, and autoimmune disorders.